| Managing dyslipidemia in chronic kidney disease: a comprehensive overview of evidence and recommendations |
Ji Yoon Kim1, Suk Min Chung2,3, and Nam Hoon Kim4
|
1Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
2Division of Nephrology, Department of Internal Medicine, Gyeonggi Provincial Geriatric Siheung Hospital, Siheung, Korea
3Division of Nephrology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
4Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea |
Corresponding Author:
Nam Hoon Kim , Tel: +82-2-920-5421, Fax: +82-2-953-9355, Email: pourlife@korea.ac.kr
|
|
Received: March 27, 2025; Revised: April 23, 2025; Accepted: May 16, 2025. |
|
|
Share : 
|
| Abstract |
|
Patients with chronic kidney disease (CKD) have a significantly increased risk of developing cardiovascular disease (CVD), making dyslipidemia management a critical component of cardiovascular risk reduction in this population. However, as the estimated glomerular filtration rate declines, distinct pathophysiological mechanisms—unlike those observed in the general population—contribute to the development and progression of CVD. Consequently, dyslipidemia management in patients with CKD requires a tailored approach that considers altered lipid profiles, comorbid conditions, and potential safety concerns associated with pharmacological therapy. This review aimed to summarize key clinical trials evaluating lipid-lowering strategies in CKD and compare current international and regional clinical practice guidelines. We assessed cardiovascular outcomes associated with various lipid-lowering agents, including statins, ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, fibrates, and omega-3 fatty acids. In addition, we discuss optimal therapeutic strategies across distinct patient subgroups, including those not treated with dialysis or kidney transplantation, those on dialysis, and kidney transplant recipients. |
| Keywords:
Dyslipidemias ; Renal insufficiency, chronic ; Hydroxymethylglutaryl-CoA reductase inhibitors ; Dialysis ; Kidney transplantation |
|
PDF Links
Full text via DOI
Download Citation
